LNP 递送 IFNα2 纳米质粒实现多区室免疫与肿瘤细胞重编程，克服结肠癌免疫治疗耐药
Multi-compartment immune and tumor cell reprogramming by IFNa2 overcomes colon cancer immunotherapy resistance
bioRxiv · 2026 年 8 月 28 日 · Zainab Tiamiyu, Patrick Czabala, Jennifer Worthy 等 13 人
约 85–90% 的结直肠癌属于微卫星稳定型，对免疫检查点抑制剂（解除免疫刹车的一大类抗癌药）耐药。研究者用一种脂质纳米颗粒（LNP，可将核酸送入细胞的微小脂肪囊）包裹编码 IFNα2（一种免疫信号细胞因子）的纳米质粒，直接转染肺转移灶的肿瘤细胞，使其成为局部持续产生 IFNα2 的来源。在同类及人源化小鼠模型中，该疗法抑制了结肠癌肺转移，并使原本耐药肿瘤对 PD-1 阻断敏感，若同时中和被诱导的 IL6 效果更好。单细胞测序显示巨噬细胞、耗竭 T 细胞和肿瘤细胞均被重编程，微环境转录特征与帕博利珠单抗应答者相似。该结果提示 LNP-IFNα2 有望成为现成可用的纳米药物，但属预印本，尚未经同行评审。
为什么推荐给您：全新纳米药物策略在动物模型中逆转 ICI 耐药，转化前景明确，但仅临床前且未同行评审。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Approximately 85-90% of colorectal cancers (CRC) are microsatellite stable and resist immune checkpoint inhibitors (ICI). The recent success of intismeran, a lipid nanoparticle (LNP)-delivered mRNA encoding patient-specific tumor antigens, enhances pembrolizumab responses, showing that LNP-delivered nucleic acids can render ICI-resistant tumors responsive by supplying what the tumor microenvironment lacks. Because an IFN-responsive phenotype predicts CRC response to checkpoint blockade and tumor cell PD-L1 represses IFN-I, we asked whether delivering the missing cytokine, rather than antigen, achieves the same conversion. Here we show that PD-1 blockade failed even when initiated before tumor seeding, yet deleting tumor cell PD-L1 abolished colon cancer lung metastasis, implicating a tumor-intrinsic PD-L1 function that antibody blockade does not neutralize. An LNP-encapsulated IFNα2-encoding nanoplasmid (LNP-IFNα2) transfected tumor cells within lung metastases, converting them into a self-sustaining and tumor-restricted IFNα2 source. LNP-IFNα2 suppressed colon cancer lung metastasis in syngeneic and humanized mouse models and sensitized these ICI-resistant tumors to PD-1 blockade. Efficacy improved further with neutralization of co-induced IL6. scRNA-Seq revealed multi-compartment reprogramming: SPP1+ macrophages acquired apoptotic signatures as IFN-responsive monocytes replaced them, progenitor-exhausted T cells exited quiescence and expanded, and tumor cells exited a high-cycling state, gained antigen presentation, and shifted away from cuproptosis resistance. The treated microenvironment transcriptionally recapitulated pembrolizumab-responder signatures, positioning LNP-IFNα2 as an off-the-shelf nanomedicine for ICI-resistant CRC.